A common osteoporosis drug blocked spinal damage in a surprising new study
Scientists have uncovered a surprising genetic connection to spinal degeneration and found that an existing osteoporosis drug can prevent damaging mineral buildup in zebrafish spines. The discovery could pave the way for new treatments that slow or prevent a major cause of chronic back pain.
Recent research has uncovered an unexpected benefit of a widely prescribed osteoporosis medication. In a groundbreaking study involving zebrafish, scientists discovered that the drug effectively blocks spinal damage, offering hope for innovative treatments for chronic neck and back pain.
The study focused on the drug's ability to prevent the formation of abnormal mineral deposits in the spine, a process that can lead to hardened tissues and fused vertebrae. These mineral deposits contribute to the gradual deterioration of the discs that cushion the spine's bones, a condition known as intervertebral disc degeneration (IVDD). IVDD is a leading cause of back pain, with most individuals experiencing it at some point in their lives.
Researchers from the Universities of Edinburgh and Bristol investigated how genetic changes, particularly those affecting collagen IX—a protein crucial for maintaining the structural integrity of spinal discs—contribute to spinal damage. By studying genetically modified zebrafish, they observed striking similarities to humans with degenerative spinal disease. The fish exhibited abnormal mineral accumulation, spinal fusion, and loss of the protective framework supporting the spine's development.
Interestingly, the researchers found that the damage occurred before mineral deposits appeared, implicating a breakdown in the protective layer during spinal development. This insight suggests that deterioration of this framework may initiate a chain reaction leading to spinal hardening.
Moreover, the study revealed intriguing molecular pathways involved in spinal degeneration. Changes in fat metabolism and vitamin A signaling were identified as key factors. Bisphosphonates, the same class of drugs used to treat osteoporosis, successfully halted the abnormal mineral buildup in zebrafish. This finding is particularly significant as it suggests that an existing treatment may also hold promise for spinal degeneration therapies.
The findings demonstrate the potential of zebrafish as a valuable tool for investigating spinal diseases and testing new treatments. While these results are promising, further research is needed to determine if the same mechanisms apply to humans and to ensure the safety and efficacy of targeting these molecular pathways in spinal disc degeneration.
Written by urgent.news from ScienceDaily Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
